Treatment of Hormone-Refractory Prostate Cancer With Docetaxel or Mitoxantrone: Relationships Between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-07-0944
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Prostate-Specific Antigen Response to Withdrawal of Megestrol Acetate in a Patient With Hormone-Refractory Prostate Cancer

Mayo Clinic Proceedings
Medicine
1997English

Prostate-Specific Antigen Response to Withdrawal of Megestrol Acetate in a Patient With Hormone-Refractory Prostate Cancer

Mayo Clinic Proceedings
Medicine
1997English

Low-Dose Docetaxel in Combination With Dexamethasone for Hormone-Refractory Prostate Cancer

Japanese Journal of Urology
Urology
2011English

Mp86-14 Prostate Specific Antigen and Health-Related Quality-Of-Life Outcomes in Uninsured Men With Prostate Cancer

Journal of Urology
Urology
2017English

Hormone-Refractory Prostate Cancer

English

Phase 1/2 Study of Preoperative Docetaxel and Mitoxantrone for High-Risk Prostate Cancer

Cancer
Cancer ResearchOncology
2010English

Achieving Treatment Goals for Hormone-Refractory Prostate Cancer With Chemotherapy

Oncologist
Cancer ResearchMedicineOncology
2005English

The Role of Prostate-Specific Antigen in Prostate Cancer Screening

Romanian Review of Laboratory Medicine
2014English

Prostate-Specific Antigen Decline After 4 Weeks of Treatment With Abiraterone Acetate and Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer

European Urology
Urology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy